Nirsevimab Effective for Preventing RSV-Linked Hospitalization
By Elana Gotkine HealthDay Reporter
FRIDAY, March 8, 2024 -- Receipt of a single dose of nirsevimab is effective for preventing respiratory syncytial virus (RSV)-associated hospitalization for infants, according to research published in the March 7 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Heidi L. Moline, M.D., from the CDC in Atlanta, and colleagues examined nirsevimab effectiveness against RSV-associated hospitalization among infants in their first RSV season during Oct. 1, 2023, to Feb. 29, 2024.
The researchers found that 8 percent of the 699 infants hospitalized with acute respiratory illness received nirsevimab at least seven days before onset of symptoms. The effectiveness of nirsevimab was 90 percent against RSV-associated hospitalization; the median time from receipt to onset of symptoms was 45 days. Nirsevimab effectiveness is expected to decrease with increasing time after receipt due to antibody decay; however, the number of infants who received nirsevimab was too low to stratify by duration from receipt.
"Receipt of a single dose of nirsevimab was highly effective against RSV-associated hospitalization in infants entering their first RSV season," the authors write. "This finding supports current CDC recommendations that all infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab to reduce the risk for RSV-associated hospitalization in their first RSV season."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Prenatal Vaccination With RSV Prefusion F Does Not Increase Risk for Preterm Birth
FRIDAY, July 12, 2024 -- Prenatal vaccination with a nonadjuvanted bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) protein subunit vaccine is not associated with...
Nirsevimab Effective Against RSV-Linked Bronchiolitis Hospitalization
WEDNESDAY, July 10, 2024 -- Nirsevimab therapy is effective for reducing the risk for hospitalization for respiratory syncytial virus (RSV)-associated bronchiolitis among infants...
Marked Increase in Pediatric RSV Hospitalizations Seen Postpandemic
TUESDAY, June 18, 2024 -- Hospital volumes for pediatric respiratory syncytial virus (RSV) rose significantly following the pandemic, along with the need for advanced respiratory...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.